VIVO BIO TECH LTD.

Vivo Bio Tech Ltd announced that its Board of Directors, in a meeting held on August 22, 2026, approved the 39th Annual General Meeting (AGM) scheduled for September 30, 2026. The board also approved the re-appointment of Mr. Kalyan Ram Mangipudi, Mr. Sri Kalyan Kompella, and Dr. Sankaranarayanan Alangudi as Whole-Time Directors. The re-appointments of Mr. Kompella and Dr. Alangudi are for a period of five years, subject to shareholder approval. The Board's Report, Corporate Governance Report, and Management Discussion and Analysis report for the financial year ended March 31, 2026, were also approved.

Vivo Bio Tech Ltd announced the outcome of its Board Meeting held on August 22, 2026. The board approved the 39th Annual General Meeting (AGM) to be held on September 30, 2026, via Video Conferencing. Key approvals also include the Board's Report, Corporate Governance Report, and Management Discussion and Analysis for the financial year ended March 31, 2026. Furthermore, the re-appointment of Mr. Kalyan Ram Mangipudi as Whole-Time Director was approved, retiring by rotation. The board also approved the re-appointment of Mr. Sri Kalyan Kompella and Dr. Sankaranarayanan Alangudi as Whole-Time Directors for five-year terms, subject to shareholder approval.

Vivo Bio Tech Ltd announced the expiry of 8,10,000 convertible equity warrants, originally allotted to promoters on February 21, 2025. These warrants, part of a larger 12,00,000 allotment, expired due to non-exercise before the 18-month tenure ending August 21, 2026. The warrants were issued at ₹45 each, comprising a face value of ₹10 and a premium of ₹35. Promoters Kompella Lopa Mudra and Kompella Modini were allotted 6,00,000 warrants each, with 3,50,000 and 4,60,000 respectively expiring.

Vivo Bio Tech Ltd has announced the expiry of 483 convertible equity warrants, originally allotted on February 20, 2025, to Antique Infotech Private Limited. These warrants, part of a larger issuance of 26,00,000 warrants at ₹45 each, expired due to non-exercise before the eighteen-month tenure concluded on August 20, 2026. The face value of each warrant was ₹10 with a premium of ₹35. This event is reported under SEBI regulations.

Vivo Bio Tech Ltd announced the outcome of its board meeting held on July 13, 2026. The board considered and approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The results were reviewed by statutory auditors M/s. P. Murali & Co. The meeting commenced at 7:00 p.m. and concluded at 7:30 p.m. Detailed financial statements along with the limited review report are enclosed.

Vivo Bio Tech Ltd announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company reported a consolidated revenue from operations of ₹1,427.97 Lacs and a net profit after tax of ₹18.76 Lacs for the quarter. Standalone revenue from operations was ₹1,413.94 Lacs with a net profit after tax of ₹18.76 Lacs. The board meeting also included the submission of the Limited Review Report by the statutory auditors, M/s. P. Murali & Co.

Vivo Bio Tech Ltd has reported, via its Registrar and Share Transfer Agent M/s. Aarthi Consultants Private Limited, that there were zero requests processed and zero requests received during the period ended June 2026 for the re-lodgement of transfer requests pertaining to physical shares. This update is in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, which provided a special window for such re-lodgements. The company is providing this information for the records and to intimate the stock exchanges.

Vivo Bio Tech Ltd has announced that its Board of Directors will convene on July 13, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. In conjunction with this meeting, the company has also declared a trading window closure for directors, promoters, designated employees, and connected persons, which will remain in effect until July 15, 2026.

Vivo Bio Tech Ltd has announced the closure of its trading window for all insiders, including designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut from July 01, 2026, until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. This measure is intended to prevent potential insider trading activities.

Vivo Bio Tech Ltd has announced a change in its Company Secretary and Compliance Officer. Mr. A V Kiran has ceased to hold the position effective June 24, 2026. The Board of Directors has authorized Mr. Bhavish Vijayvargiya to act as the Company Secretary & Compliance Officer. Mr. Vijayvargiya will be responsible for determining the materiality of events and advising on disclosures to the stock exchanges. His contact details have been provided for official communication.